Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Short Interest Update

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Get Free Report) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 2,770,000 shares, a decrease of 12.9% from the December 31st total of 3,180,000 shares. Approximately 3.7% of the company's shares are short sold. Based on an average daily trading volume, of 309,000 shares, the short-interest ratio is currently 9.0 days.

Insider Activity

In other news, Director Franklin M. Berger sold 359,606 shares of the business's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total value of $1,024,877.10. Following the sale, the director now directly owns 451,897 shares of the company's stock, valued at approximately $1,287,906.45. The trade was a 44.31 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 17.80% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. American Century Companies Inc. raised its holdings in shares of Atea Pharmaceuticals by 14.6% in the 2nd quarter. American Century Companies Inc. now owns 125,169 shares of the company's stock valued at $414,000 after purchasing an additional 15,911 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Atea Pharmaceuticals by 55.2% in the second quarter. Dimensional Fund Advisors LP now owns 594,360 shares of the company's stock valued at $1,968,000 after buying an additional 211,428 shares during the last quarter. Marshall Wace LLP acquired a new stake in Atea Pharmaceuticals in the second quarter valued at $603,000. The Manufacturers Life Insurance Company lifted its holdings in Atea Pharmaceuticals by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,886 shares of the company's stock worth $115,000 after buying an additional 4,339 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Atea Pharmaceuticals by 117.9% during the 3rd quarter. SG Americas Securities LLC now owns 30,612 shares of the company's stock worth $103,000 after acquiring an additional 16,561 shares in the last quarter. Hedge funds and other institutional investors own 86.67% of the company's stock.

Atea Pharmaceuticals Price Performance

Shares of NASDAQ AVIR traded up $0.05 during midday trading on Tuesday, hitting $2.97. The company's stock had a trading volume of 241,422 shares, compared to its average volume of 424,137. The firm has a market capitalization of $250.85 million, a price-to-earnings ratio of -1.43 and a beta of 0.19. The business's fifty day simple moving average is $3.21 and its two-hundred day simple moving average is $3.44. Atea Pharmaceuticals has a 1 year low of $2.75 and a 1 year high of $4.60.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.13. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. Analysts anticipate that Atea Pharmaceuticals will post -2.01 EPS for the current fiscal year.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.